Peptide library

Often split AM/PM for gut protocols, or injected near the site of injury for local repair.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 250 mcg dose = 0.1 mL

Gut- and tissue-repair blend, typically GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg in one vial. Blend ratios vary by supplier — confirm the mg of each component on your COA before dosing.

At 80 mg in 3 mL → 26.67 mg/mL · 266.7 mcg per unit · one 500 mcg dose = 0.019 mL

Loading phase twice weekly for 4–6 weeks, then maintenance every 2–4 weeks.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 2.5 mg dose = 1 mL

Commonly stacked with CJC-1295 (no DAC). Take fasted; avoid food 2h before / 30 min after.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 250 mcg dose = 0.1 mL

Short-acting GHRH analog, usually dosed AM fasted and pre-bed.

At 2 mg in 2 mL → 1 mg/mL · 10 mcg per unit · one 100 mcg dose = 0.1 mL

Long-acting; dosed once or twice weekly rather than daily.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 2 mg dose = 0.8 mL

Dosed at bedtime to align with the natural nocturnal GH pulse.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 250 mcg dose = 0.1 mL

Cycled tightly — receptor desensitization is the main reason for short cycles.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 150 mcg dose = 0.06 mL

EGRIFTA SV: a 2 mg vial reconstituted with 0.5 mL sterile water, 1.4 mg (0.35 mL) once daily at bedtime. Approved only for HIV-associated lipodystrophy.

At 2 mg in 0.5 mL → 4 mg/mL · 40 mcg per unit · one 1.4 mg dose = 0.35 mL

Once weekly. The ladder above is the approved Wegovy escalation; the maintenance dose is reached at week 17.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 250 mcg dose = 0.1 mL

Once weekly. 2.5 mg is a starting dose, not a treatment dose; the label raises it in 2.5 mg steps no sooner than every 4 weeks, to a 15 mg maximum.

At 30 mg in 2 mL → 15 mg/mL · 150 mcg per unit · one 2.5 mg dose = 0.167 mL

Investigational — no approved dose exists. Phase 3 TRIUMPH-1 randomised 4, 9 and 12 mg once weekly, every arm starting at 2 mg and escalating over 16 weeks. The earlier phase 2 trial used 1, 4, 8 and 12 mg; 8 mg is not a phase 3 dose.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 2 mg dose = 0.4 mL

Commonly run 5-on / 2-off, dosed fasted in the morning.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 300 mcg dose = 0.12 mL

Not a peptide — a small-molecule NNMT inhibitor, and the route it is actually used by is oral capsule. Injectable use is far less standardized and community figures for it disagree by roughly tenfold; the 500 mcg default here is the low end of that spread, chosen deliberately. Oral and subcutaneous amounts are not interchangeable and cannot be converted between routes, and no human study has compared them. All figures are community reference points, not a validated dose.

At 50 mg in 5 mL → 10 mg/mL · 100 mcg per unit · one 500 mcg dose = 0.05 mL

Mitochondrial-derived peptide; commonly 2–3x weekly or on a fixed interval such as every 5 days, in short blocks.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 5 mg dose = 1 mL

Zadaxin labelling: 1.6 mg twice weekly (e.g. Mon and Thu) for six months. Approved outside the US, not by the FDA.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 1.6 mg dose = 0.32 mL

Classic Khavinson pattern: a 10–20 day course, one or two courses per year.

At 50 mg in 5 mL → 10 mg/mL · 100 mcg per unit · one 5 mg dose = 0.5 mL

Inject slowly — rapid administration is the usual cause of flushing and chest tightness.

At 500 mg in 10 mL → 50 mg/mL · 500 mcg per unit · one 75 mg dose = 1.5 mL

Light-sensitive; keep the vial shielded from sunlight.

At 1200 mg in 10 mL → 120 mg/mL · 1,200 mcg per unit · one 400 mg dose = 3.333 mL

Investigational. The MMPOWER-3 mitochondrial myopathy trial used 40 mg once daily by subcutaneous injection and did not meet its primary endpoint.

At 50 mg in 2 mL → 25 mg/mL · 250 mcg per unit · one 40 mg dose = 1.6 mL

Taken shortly before bed; some run it every other night.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 200 mcg dose = 0.08 mL

Vyleesi label: 1.75 mg at least 45 minutes before anticipated activity, no more than 1 dose in 24 hours and no more than 8 doses per month. Used as needed rather than on a fixed day.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 1.75 mg dose = 0.35 mL

Mostly research protocols; dosing is weight-based in the literature.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 1 mg dose = 0.4 mL

Frequently used topically instead of injected. Copper peptide — keep away from light.

At 50 mg in 2 mL → 25 mg/mL · 250 mcg per unit · one 1.5 mg dose = 0.06 mL

Start at the low end and titrate. Degrades faster than most peptides — use within ~2–3 weeks of reconstitution.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 250 mcg dose = 0.05 mL

The approved afamelanotide product is a 16 mg implant given every 2 months for a rare light-sensitivity disorder, not an injected daily dose — the figures here are community convention. More selective than Melanotan II, so fewer flushing and nausea reports.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 500 mcg dose = 0.1 mL

Investigational. Phase 2 work in sarcoidosis small-fibre neuropathy used 4 mg daily for 28 days, which is the 28-day course set here.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 4 mg dose = 0.8 mL

Investigational long-acting amylin analogue, weekly. Registrational trials pair it with semaglutide and escalate both to 2.4 mg — stack cautiously and change one compound at a time.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 250 mcg dose = 0.1 mL

Pre-mixed 5 mg CJC-1295 (no DAC) + 5 mg Ipamorelin in one vial, so each draw delivers equal mcg of both. Dose fasted AM and pre-bed.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 200 mcg dose = 0.04 mL

Skin/hair/tissue blend, typically GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg in one vial. Ratios vary by supplier — confirm the mg of each component on your COA.

At 70 mg in 3 mL → 23.33 mg/mL · 233.3 mcg per unit · one 700 mcg dose = 0.03 mL

Even 50/50 split of BPC-157 and TB-500 in one vial, so a 500 mcg draw is ~250 mcg of each. Common injury-recovery pairing.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 500 mcg dose = 0.1 mL

Anti-inflammatory tripeptide used for gut and skin protocols; also run orally or topically rather than injected.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 400 mcg dose = 0.08 mL

Antimicrobial peptide; start very low — injection-site reactions and flu-like effects are common at higher doses. Short courses only.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 100 mcg dose = 0.04 mL

Anxiolytic tuftsin analog, most often used intranasally in 10–14 day blocks.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 300 mcg dose = 0.06 mL

Nootropic ACTH(4-10) analog, usually intranasal in the morning for short 10–14 day courses.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 300 mcg dose = 0.06 mL

Not a peptide — a lipotropic blend (methionine, inositol, choline + B12) sold alongside them. Usually dosed by volume weekly rather than by mcg.

At 120 mg in 10 mL → 12 mg/mL · 120 mcg per unit · one 12 mg dose = 1 mL

A senolytic studied only in cells and mice. No human trial has ever been run, so no dose is established. Published work also includes a finding that clearing senescent cells made pulmonary hypertension worse in mice — the effect is not uniformly beneficial.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 5 mg dose = 1 mL

An angiotensin IV analogue acting on the HGF/c-Met system, studied in rodents and cell culture. No human trial has been published, so no dose is established.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 1 mg dose = 0.2 mL

A tripeptide, Ala-Glu-Asp. Not the same compound as Epitalon, which is the tetrapeptide Ala-Glu-Asp-Gly — nearly all the published 'AED' literature is actually about Epitalon. Almost nothing studies AED itself.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 1 mg dose = 0.2 mL

A tripeptide, Glu-Asp-Arg. The published work is overwhelmingly rat and cell-culture studies from one Russian research group; the few papers involving people do not describe a controlled trial.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 1 mg dose = 0.2 mL

A PubMed search returns no research on this compound at all. Vendor pages describe it as a modified Semax analogue, but they do not agree on its structure, and the claims made for it rest on Semax studies rather than on anything published about Adamax.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 300 mcg dose = 0.06 mL

Investigational selective amylin receptor agonist. Unlike most of this library it has real published human data — a 48-week phase 2 trial in The Lancet — but it is not approved anywhere.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 1 mg dose = 0.2 mL

Not a peptide — a synthetic small molecule that activates the estrogen-related receptors, studied as an 'exercise mimetic'. All published work is animal and cell research; no human has been dosed in a published study.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 500 mcg dose = 0.1 mL

Not a peptide — a vitamin. Cyanocobalamin injection is an approved medicine for B12 deficiency and pernicious anaemia, and usually comes ready-mixed rather than as a powder to reconstitute. Injecting it when you are not deficient has no established benefit.

At 30 mg in 30 mL → 1 mg/mL · 10 mcg per unit · one 1 mg dose = 1 mL

The natural hypothalamic hormone that tells the pituitary to release LH and FSH. It has a real human approval history in the US — as a diagnostic agent and, as Lutrepulse, for ovulation induction — but the product currently listed under the Factrel name is a cattle medicine.

At 2 mg in 2 mL → 1 mg/mL · 10 mcg per unit · one 100 mcg dose = 0.1 mL

An approved prescription medicine with a real label, dosed in USP units rather than mcg — the calculator's mcg figures do not apply to it. Approved for cryptorchidism, selected male hypogonadotropic hypogonadism and ovulation induction. Its label carries a boxed warning that it does not work for weight loss.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 1 mg dose = 0.2 mL

Not a single peptide — a mixture of peptides and amino acids derived from pig brain tissue, sold ready-mixed, so there is nothing to reconstitute. Approved in some countries but not the US. Cochrane's 2023 review found no benefit in stroke and a possible increase in non-fatal serious adverse events.

At 0 mg in 0 mL → 0 mg/mL · 0 mcg per unit · one — dose = 0 mL

A 28-amino-acid signalling peptide. As aviptadil it was put through real randomised trials in critical COVID-19 — which did not show a benefit — by intravenous infusion in hospital. Nothing in that work supports the doses or routes discussed online.

At 5 mg in 2 mL → 2.5 mg/mL · 25 mcg per unit · one 50 mcg dose = 0.02 mL

A thymus-derived peptide preparation from the same Russian research tradition as Pinealon and Epitalon. It is a mixture rather than a defined molecule, and the published work has not been independently replicated.

At 10 mg in 2 mL → 5 mg/mL · 50 mcg per unit · one 10 mg dose = 2 mL

A modified IGF-1 built as a cell-culture reagent: the changes make it resist the binding proteins that normally control IGF-1 in the body. It has never been trialled in people. Recombinant human IGF-1 (mecasermin) is a different, approved medicine.

At 1 mg in 2 mL → 0.5 mg/mL · 5 mcg per unit · one 50 mcg dose = 0.1 mL

A PEGylated version of a peptide derived from an IGF-1 splice variant. The PEGylated form studied in community protocols has no published human research of its own.

At 2 mg in 2 mL → 1 mg/mL · 10 mcg per unit · one 200 mcg dose = 0.2 mL

A copper-binding tripeptide used in cosmetic formulations, usually discussed for hair. Related to GHK-Cu but a different sequence with far less research behind it.

At 50 mg in 5 mL → 10 mg/mL · 100 mcg per unit · one 2 mg dose = 0.2 mL

A cosmetic ingredient applied to the skin, marketed as a topical alternative to botulinum toxin. It is formulated into creams, not injected, and the supporting data is largely manufacturer-generated.

At 10 mg in 5 mL → 2 mg/mL · 20 mcg per unit · one 1 mg dose = 0.5 mL

Three compounds in one vial. Each is covered by its own entry; none has a human dosing trial. Blend ratios vary by supplier, so the mg of each component has to come off your COA before any dose figure means anything.

At 30 mg in 3 mL → 10 mg/mL · 100 mcg per unit · one 500 mcg dose = 0.05 mL

Two compounds in one vial, both with their own entries. Ratios vary by supplier — check the COA.

At 60 mg in 3 mL → 20 mg/mL · 200 mcg per unit · one 500 mcg dose = 0.025 mL

A supplier blend of BPC-157, TB-500 and Cartalax. All three have their own entries and none has human dosing data; Cartalax has almost no research of any kind. The name is marketing, not a formulation standard — contents vary.

At 30 mg in 3 mL → 10 mg/mL · 100 mcg per unit · one 500 mcg dose = 0.05 mL

Three metabolic compounds in one vial, each with its own entry. 5-Amino-1MQ is not a peptide. The components have very different typical doses, so the blend ratio decides everything — read the COA.

At 100 mg in 3 mL → 33.33 mg/mL · 333.3 mcg per unit · one 5 mg dose = 0.15 mL

Two Russian-developed peptides in one vial, each with its own entry. Combining them has not been studied; the research that exists is on each one separately.

At 20 mg in 3 mL → 6.67 mg/mL · 66.7 mcg per unit · one 500 mcg dose = 0.075 mL

A GHRH analogue plus a ghrelin-receptor agonist in one vial, each with its own entry. Tesamorelin alone is an approved medicine with a label; this combination is not, and pairing them has not been trialled.

At 12 mg in 3 mL → 4 mg/mL · 40 mcg per unit · one 1 mg dose = 0.25 mL